
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
1980, FDA requires IRB review for NSR (non-significant risk) devices1981, FDA and Department of Health and Human Services revise regulations for human subject protection.






